A few weeks ago, Kathryn Thomas used the word ‘enormity’ incorrectly on national television, and so far as I can surmise, about a dozen people noticed. She should have said ‘enormousness’, if the particular substance of the root (e- (variant of ex-) ‘out of’ + norma ‘pattern, standard.

http://www.imt.ie/opinion/2008/10/how_to_look_like_youre_trying.html

Samaritan Partners 'Forgetful' Rat Model to Taconic to Commercialize

Press Release | www.prnewswire.com | Oct 1, 2008

The Samaritan Alzheimer's Rat Model - Mimics Human Alzheimer's - Speeds 'Race for Time' to Find Cure - Saves Valuable Research Money LAS VEGAS, Oct. 1 /PRNewswire-FirstCall/ -- Samaritan Pharmaceuticals (OTC Bulletin Board: SPHC) (http://www.samaritanpharma.

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/10-01-2008/0004895815&EDATE=

Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound (PR Newswire)

News | biz.yahoo.com | Oct 1, 2008

Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound. - INDIANAPOLIS, Oct. 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY - News) today announced it will begin enrolling patients in a second Phase III study of LY450139, a

http://biz.yahoo.com/prnews/081001/clw009.html?.v=101

The Pfizer Memo (at Forbes.com)

News | www.forbes.com | Sep 30, 2008

Here is the memo in which Pfizer's research chief outlines the company's research priorities.

http://www.forbes.com/2008/09/30/pfizer-drug-agenda-biz-bizhealth-cx_mh_0930pfizermemo.html?partner=yahootix

Pfizer says R&D pipeline advancing ahead of schedule (at MarketWatch)

News | www.marketwatch.com | Sep 30, 2008

Pfizer Inc., which has faced chronic erosion of its top line due to increased competition from generic drugs, announced Tuesday that its research and development efforts to fill its pipeline are running ahead of schedule.

http://www.marketwatch.com/news/story/pfizer-says-rd-pipeline-advancing/story.aspx?guid=%7B66453CA1%2DF502%2D4532%2DBEAF%2D485658745562%7D&siteid=yhoof

Link Medicine Completes $40 Million Series C Financing to Accelerate Development of First Disease-Modifying Treatments for Neurodegenerative Disorders

News | www.biospace.com | Sep 30, 2008

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Link Medicine Corporation, a privately held biotechnology company advancing novel approaches for the treatment of neurodegenerative diseases, announced today that it has obtained $40 million of Series C equity financing to help move its lead preclinical programs

http://www.biospace.com/news_story.aspx?StoryID=111363&full=1

U.S. Stem Cell Market - Current Developments

News | www.frost.com | Sep 30, 2008

This research service covers the U.S. stem cell market: current developments. Included are a disease overviews for main indications, estimated patient penetration for main indications, technology trends,and total market potential. The market is segmented by cell type: adult stem cell and embryonic

http://www.frost.com/prod/servlet/report-homepage.pag?Src=RSS&repid=N48B-01-00-00-00

Medical notes - Look after your brain, as you only have the one

News | news.scotsman.com | Sep 24, 2008

Medical notes - Look after your brain, as you only have the one - TV presenter Fiona Phillips has been told there is a chance she will develop early-onset Alzheimer's, so what can the rest of us do to minimise the risk?

http://news.scotsman.com/health/Medical-notes--Look-after.4520358.jp